Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN4035 in Advanced Solid Tumors
NCT07686445Phase 1Recruiting
- Sponsor
- Adlai Nortye
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of AN4035 in solid tumor (2 arms), sponsored by Adlai Nortye. Primary endpoints: Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Started Sep 2026; status: recruiting.
02
Drugs
AN4035
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07686445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686445.